文献速递心脑血管急症复苏、休克与脓毒症

吗啡对急性心肌梗死患者P2Y12血小板抑制剂的影响:一项Meta分析

Effects of morphine on P2Y12 platelet inhibitors in patients with acute myocardial infarction: A meta-analysis.
PubMed 文献 · Am J Emerg Med · 2020-11-21
一句话结论在AMI患者中,吗啡降低替格瑞洛Cmax并升高血小板反应性及HRPR,但死亡率和呕吐需权衡。

该Meta分析纳入13项研究共5688例AMI患者(吗啡组2014例,对照组3674例),评估吗啡对P2Y12血小板抑制剂的影响。结果显示吗啡组血小板反应性(SMD 0.834,95%CI 0.483-1.186)和HRPR率(RR 1.994,95%CI 1.536-2.588)更高,替格瑞洛Cmax更低(WMD -481.838,95%CI -841.242至-122.434),死亡率更低(RR 0.561,95%CI 0.337-0.933),呕吐率更高(RR 4.486,95%CI 2.263-8.891)。提示吗啡可能抑制P2Y12抑制剂抗血小板效应,临床需关注血小板反应性及替格瑞洛浓度。

要点

  • 吗啡组较对照组血小板反应性显著升高(SMD 0.834,95%CI 0.483-1.186,P<0.001)。
  • 吗啡组高残余血小板反应性(HRPR)风险是对照组的1.994倍(95%CI 1.536-2.588,P<0.001)。
  • 吗啡组替格瑞洛Cmax较对照组降低(WMD -481.838,95%CI -841.242至-122.434,P=0.009)。
  • 吗啡组死亡率低于对照组(RR 0.561,95%CI 0.337-0.933,P=0.026),但呕吐率更高(RR 4.486,95%CI 2.263-8.891)。
  • 吗啡可能抑制P2Y12抑制剂抗血小板作用,需警惕HRPR及替格瑞洛暴露降低。

适用人群与场景

  • 急性心肌梗死(AMI)患者,包括接受P2Y12血小板抑制剂治疗者;吗啡组2014例,对照组3674例。

诊断标准与关键阈值

  • 高残余血小板反应性(HRPR)定义及检测方法原文未提及。

处置流程与药物剂量

  • 原文未提及具体药物剂量、给药途径、频次或目标值。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • Meta分析纳入13项研究共5688例AMI患者(吗啡组2014例,对照组3674例)。
  • 吗啡组较对照组血小板反应性更高(SMD 0.834,95%CI 0.483-1.186,P<0.001)。
  • 吗啡组HRPR率更高(RR 1.994,95%CI 1.536-2.588,P<0.001)。
  • 吗啡组替格瑞洛Cmax更低(WMD -481.838,95%CI -841.242至-122.434,P=0.009)。
  • 吗啡组死亡率更低(RR 0.561,95%CI 0.337-0.933,P=0.026)。
  • 吗啡组呕吐率更高(RR 4.486,95%CI 2.263-8.891,P<0.001)。
  • 其他结局(再梗死、卒中、支架血栓、TIMI出血、呼吸困难、造影剂肾病、肺水肿)原文未给出具体结果。

证据类型、等级与局限

  • 证据类型:系统评价/Meta分析;检索PubMed、Embase、Cochrane Library和Web of Science至2019年5月11日。
  • 局限性:原文未明确提及;纳入研究设计可能影响异质性(I2值原文未完整给出)。

对床旁实践的改变

  • 对于接受P2Y12抑制剂(尤其是替格瑞洛)的AMI患者,使用吗啡可能降低替格瑞洛Cmax并增加HRPR风险,需监测血小板反应性。
  • 吗啡可能降低死亡率但增加呕吐,临床决策需个体化权衡。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To explore the effects of morphine on P2Y12 platelet inhibitors in patients with acute myocardial infarction (AMI).

METHODS: PubMed, Embase, Cochrane Library, and Web of Science were used to retrieve literature through 11th May 2019. Standardized weighted mean difference (SMD) and relative risk (RR) with 95% confidence intervals (CI), P-value, and I2 value were used to assess the strength of the association in this meta-analysis. Outcomes included platelet reactivity, high residual platelet reactivity (HRPR), ticagrelor maximum concentration (Cmax), ticagrelor area under curve (AUC), death rate, reinfarction rate, stroke, stent thrombosis, thrombolysis in myocardial infarction (TIMI) hemorrhage, dyspnea, emesis, contrast-induced nephropathy, and pulmonary edema.

RESULTS: A total of 13 articles were included in this study, containing 5688 patients (morphine group: n = 2014, control group: n = 3674). Results illustrated that the morphine group had a higher platelet reactivity (SMD: 0.834, 95%CI: 0.483-1.186, P < 0.001) and HRPR rate (RR: 1.994, 95%CI: 1.536-2.588, P < 0.001) than the control group, while the Cmax of ticagrelor (WMD: -481.838, 95%CI: -841.242-122.434, P = 0.009) was lower than that of the control group. The death rate of the morphine group was lower than that in the control group (RR: 0.561, 95%CI: 0.337-0.933, P = 0.026). The morphine group had a higher emesis rate than the control group (RR: 4.486, 95%CI: 2.263-8.891, P < 0.001).

CONCLUSION: Morphine effectively suppresses the inhibition effect of P2Y12 platelet inhibitors in patients with AMI.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Zhang Y, Wang N, Gu Q, et al. Effects of morphine on P2Y12 platelet inhibitors in patients with acute myocardial infarction: A meta-analysis. Am J Emerg Med. 2020. PMID: 33317866. doi:10.1016/j.ajem.2020.11.003

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。